BIOPHARMACEUTICS & DRUG DISPOSITION

Scope & Guideline

Empowering Discoveries in Biopharmaceutics

Introduction

Welcome to the BIOPHARMACEUTICS & DRUG DISPOSITION information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of BIOPHARMACEUTICS & DRUG DISPOSITION, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0142-2782
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1979 to 2024
AbbreviationBIOPHARM DRUG DISPOS / Biopharm. Drug Dispos.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Biopharmaceutics & Drug Disposition' focuses on the intricate relationships between drug formulation, absorption, metabolism, and the pharmacokinetics/pharmacodynamics of therapeutic agents. It aims to provide a platform for research that advances the understanding of drug disposition in biological systems, particularly through innovative modeling approaches.
  1. Pharmacokinetics and Pharmacodynamics:
    The journal emphasizes studies that explore the pharmacokinetic and pharmacodynamic profiles of drugs, including their absorption, distribution, metabolism, and excretion (ADME) characteristics in various populations and conditions.
  2. Physiologically-Based Pharmacokinetic (PBPK) Modeling:
    A significant focus is on the development and application of PBPK models to predict drug behavior across different species and populations, facilitating better drug development and personalized medicine.
  3. Drug-Drug Interactions and Metabolism:
    Research on the interactions between drugs, particularly those mediated by metabolic enzymes and transporters, is a core area of interest, providing insights into safety and efficacy.
  4. Biopharmaceutical Characterization:
    The journal publishes studies on the biopharmaceutical properties of drug formulations, including novel drug delivery systems and their impact on pharmacokinetics.
  5. Clinical Applications and Case Studies:
    It also includes clinical studies that illustrate the application of pharmacokinetic principles in real-world settings, particularly in special populations such as pediatrics and the elderly.
The journal has been responsive to emerging trends in drug disposition research, with a significant increase in publications addressing innovative methodologies and contemporary issues in pharmacokinetics and drug delivery.
  1. Integration of Artificial Intelligence and Machine Learning:
    Recent publications show a growing trend in the application of AI and machine learning techniques to enhance drug development processes, particularly in predicting pharmacokinetic behaviors.
  2. Focus on Special Populations:
    There is an increasing emphasis on pharmacokinetics in special populations, including pediatrics, geriatrics, and patients with comorbidities, reflecting a broader understanding of individualized therapy.
  3. In Vitro-In Vivo Extrapolation (IVIVE) Studies:
    The use of IVIVE approaches to predict human pharmacokinetics from animal data is trending, which aligns with the need for more efficient drug development pathways.
  4. Advancements in Drug Delivery Systems:
    Innovative drug delivery methods, such as nanotechnology and sustained-release formulations, are gaining prominence, focusing on improving bioavailability and therapeutic outcomes.
  5. Environmental and Ecological Pharmacokinetics:
    Emerging research is increasingly exploring the pharmacokinetics of drugs in environmental contexts, addressing concerns related to drug residues and ecological impacts.

Declining or Waning

While the journal has established a strong repertoire in certain research areas, some themes have seen a decline in focus over recent years. This may be indicative of shifting research priorities or advancements in technology that have rendered previous approaches less relevant.
  1. Traditional Drug Metabolism Studies:
    There has been a noticeable decrease in the publication of studies solely focused on traditional in vitro drug metabolism assays, as newer methodologies such as PBPK modeling become more prevalent.
  2. General Population Pharmacokinetics:
    Research centered on general population pharmacokinetics without consideration for specific subpopulations (like pediatrics or geriatrics) appears to be waning, reflecting a shift towards more tailored pharmacokinetic studies.
  3. Basic Mechanistic Studies without Clinical Relevance:
    Papers that do not bridge the gap between basic mechanistic studies and clinical relevance are becoming less common, as the journal emphasizes translational research that directly impacts clinical practice.

Similar Journals

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Exploring the interface of formulation and biology.
Publisher: ELSEVIERISSN: 0939-6411Frequency: 9 issues/year

European Journal of Pharmaceutics and Biopharmaceutics is a leading academic journal published by Elsevier, dedicated to advancing the field of pharmaceutical sciences through high-quality research. Established in 1991, this multidisciplinary journal offers a platform for the dissemination of innovative findings in pharmaceutics and biopharmaceutics, covering crucial aspects such as drug formulation, delivery systems, and the interface of pharmaceutical formulation with biological systems. The journal is well-regarded for its impact, earning a Q1 status in Pharmaceutical Science and consistent Q2 rankings in both Biotechnology and Medicine (Miscellaneous) categories in 2023, thereby highlighting its significance in the scientific community. With an impressive Scopus ranking of 26th percentile in Pharmaceutical Science and 60th percentile in Biotechnology, it positions itself firmly at the forefront of research, supporting researchers, professionals, and students in their quest to address complex health challenges. While the journal does not offer an open-access option, it facilitates a rigorous peer-review process, ensuring that published articles meet the highest standards of scientific integrity. For those looking to make meaningful contributions to the field, the European Journal of Pharmaceutics and Biopharmaceutics serves as an essential resource and reference point.

CURRENT DRUG METABOLISM

Advancing the Frontiers of Drug Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-2002Frequency: 14 issues/year

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Advancing cancer treatment through innovative pharmacology.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Clinical Pharmacology in Drug Development

Bridging research and practice in drug development.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

International Journal of Pharmacology

Championing Knowledge in Pharmacology and Pharmaceutics
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Elevating Pharmaceutical Science through Rigorous Research
Publisher: ELSEVIERISSN: 0928-0987Frequency: 15 issues/year

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

BMC Pharmacology & Toxicology

Shaping the landscape of toxicological research.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Empowering healthcare through innovative pharmacological research.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Unveiling the Mechanisms of Drug Action
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1567-567XFrequency: 6 issues/year

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.

DRUG METABOLISM REVIEWS

Exploring the intricacies of drug metabolism.
Publisher: TAYLOR & FRANCIS LTDISSN: 0360-2532Frequency: 4 issues/year

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.